Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis.
OBJECTIVE
To investigate hypothalamic-pituitary-adrenal axis activity in well-defined multiple sclerosis (MS) patient subgroups.


METHODS
A total of 173 patients with clinically definite MS were studied: 40 with primary progressive, 41 with secondary progressive, 58 with relapsing-remitting in remission, and 34 with relapsing-remitting during acute relapse. Sixty healthy subjects served as controls. No patients were receiving steroid or other immunomodulatory therapy. Plasma cortisol, adrenocorticotropic hormone (ACTH), and dehydroepiandrosterone sulfate (DHEAS), as well as urine cortisol levels, were measured using commercial radioimmunoassays. Glucocorticoid receptor (GR)-binding assay in peripheral blood mononuclear cells (PBMCs) was performed using [(3)H]dexamethasone (Dex). PBMC production of the proinflammatory peptide corticotrophin-releasing hormone (CRH), interleukin (IL)-1beta, IL-6, interferon (IFN)-gamma, and tumor necrosis factor (TNF)-alpha was evaluated using enzyme-linked immunosorbent spot assay.


RESULTS
All four groups of patients displayed significantly higher cortisol, ACTH, and DHEAS plasma concentrations and urine cortisol values than controls. Although 62% of MS patients did not suppress Dex, suppression test results did not correlate with IL-1beta, IL-6, IFN-gamma, or TNF-alpha production. GR-binding assays showed no differences in binding sites between patients and controls; however, all MS groups showed decreased GR affinity and sensitivity compared with controls. The numbers of IL-1beta-, IL-6-, and TNF-alpha-secreting cells increased significantly in relapsing-remitting MS patients only during exacerbations; in contrast, IFN-gamma-secreting cells increased during both exacerbations and remission. Finally, PBMC CRH-secreting cell numbers were considerably greater in all forms of MS.


CONCLUSIONS
Patients with multiple sclerosis show hypothalamic-pituitary-adrenal axis hyperactivity, with lymphocytes expressing similar glucocorticoid receptor numbers to controls; however, binding affinity and glucocorticoid sensitivity of these lymphocytes seem to be reduced.
Ysrraelit
María C
MC
Department of Neurology, Raúl Carrea Institute for Neurological Research, FLENI, Buenos Aires, Argentina.
Gaitán
María I
MI
Lopez
Analía S
AS
Correale
Jorge
J
D000328:Adult; D015415:Biomarkers / Q000097:blood; D016207:Cytokines / Q000097:blood; D004700:Endocrine System Diseases / Q000175:diagnosis / Q000276:immunology* / Q000503:physiopathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005938:Glucocorticoids / Q000097:blood / Q000652:urine; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000276:immunology* / Q000503:physiopathology; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D009103:Multiple Sclerosis / Q000150:complications*; D015213:Neuroimmunomodulation / Q000276:immunology; D010907:Pituitary Hormones / Q000097:blood / Q000652:urine; D010913:Pituitary-Adrenal System / Q000276:immunology* / Q000503:physiopathology; D011863:Radioimmunoassay; D011965:Receptors, Glucocorticoid / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D015854:Up-Regulation / Q000276:immunology
D015415:Biomarkers; D016207:Cytokines; D005938:Glucocorticoids; D010907:Pituitary Hormones; D011965:Receptors, Glucocorticoid